The performance of companies tied to the drug's legacy presents a complex investment scenario . While the initial surge generated substantial gains, generic competition have significantly impacted sales . Investing in connected pharmaceutical firms now requires a thorough assessment of patent safeguards, evolving medical changes, and the possibilit